Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

e22528Background: Soft tissue sarcomas (STSs) are a rare group of neoplasms without curative potential in the metastatic setting. Pazopanib(P) and taxanes(T) are active agents supported in the NCCN guidelines for treatment of STSs. Methods: In a series of patients screened between August 2012 and December 2015 we combined pazopanib 200-800 mg PO daily with docetaxel 36 mg/m2 IV Q14d or paclitaxel 75mg/m2 IV D1,8,15 per 28d cycles. We describe a retrospective review of our data including PFS, mOS, CBR, ORR, and AEs. Results: Nine patients were evaluable for data collection. Common histological subtypes included: Synovial, myxofibrosarcoma, epithelioid angiosarcoma, chondrosarcoma, epithelioid, high grade sarcoma, angiosarcoma, desmoid tumor, (all n = 1) and leiomyosarcoma (n = 2). At the time of analysis, patients had received 156 cycles of pazopanib, mean 17.3, 53 cycles of docetaxel, mean 7.5, and 28 cycles of paclitaxel, mean 14. The clinical benefit rate (CBR) was 100% (1 CR, 1 near CR, 5 SD, and 2 PR)...